The company still expects the phase 2 stage of its phase 1b/2 trial of AST-008 in patients with advanced or metastatic Merkel cell carcinoma or cutaneous squamous cell carcinoma to begin in Q2.
As of Feb. 29, the company has a cash balance of $107.7 million, it said.
Price: 1.3700, Change: +0.0500, Percent Change: +3.79
|Analysts' Raise Q2, 2020, 2021 Consensus Estimates f...|
|Q2 Estimates for Laboratory Corp of America Holdings...|
|Analysts Lower Lear Corp's Q2, 2020, and 2021 Earnin...|
|KLA's 2020, 2021, and Q4 Earnings Estimates Reduced|
|Nordstrom's Q2 and 2021 Estimates Lowered but 2022 E...|